Condition: Obesity · Sponsor: Arrowhead Pharmaceuticals
This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (in Part 1), the safety, tolerability, PK, and PD of multiple doses of ARO-INHBE either as monotherapy, or in combination with tirzepatide, in adult participants with obesity with and without type 2 diabetes mellitus (in Part 2 and Part 3).
This description comes directly from the study's public registry record.
Medical Monitor · 626-304-3400 · AROINHBE@arrowheadpharma.com
Always discuss trial participation with your own doctor first.
| Research Site 1 | Grafton, Auckland, New Zealand | Recruiting |
| Research Site 5 | Auckland, New Zealand | Recruiting |
| Research Site 3 | Auckland, New Zealand | Recruiting |
| Research Site 2 | Christchurch, New Zealand | Recruiting |
| Research Site 4 | Hamilton, New Zealand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06700538